Company intelligence / Profile preview

Diagen AI

Vancouver, British Columbia, Canadadiagen.ai ↗

Ownership: Private
Development stage: Other

Overview

Diagen AI has developed a proprietary generative AI platform (“DIA”) to accelerate the design of novel proteins and peptides for applications in drug discovery, diagnostics, vaccines, and biosensors. The company collaborates with small and medium enterprises to drive innovation in precision medicine and longevity but does not report clinical results or late-stage assets as of June 2025.

Modalities: ProteinPeptides
Industry: Drug Discovery Services

Partnerships

Frontier IP Group (investor/partner)Creative Destruction Lab (investor/partner)Partnership program with small/medium enterprises in drug discovery, diagnostics & vaccines

Beyond the preview

Go deeper on Diagen AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diagen AI.

Explore the full profile